UNSPSC 51172466: Dehydrocholic acid/homatropine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA900. This VA Drug Class (GA900) classifies this compound as belonging to the group GASTRIC MEDICATIONS, OTHER.

UNSPSC 51172466 Dehydrocholic acid/homatropine (Commodity) shows negligible alignment between the code's nominal pharmaceutical scope and recent state and local procurement activity. The three most-recent opportunities tagged under this code involve offender drug testing services, a pharmacy benefit program information-gathering initiative, and generic multi-source pharmaceutical distribution through cooperative purchasing — none of which specifically target dehydrocholic acid or homatropine products. The code appears to reflect a misclassification or legacy taxonomy assignment rather than active procurement demand for this pharmaceutical compound.

Recent activity spans Texas state agencies (Texas Health and Human Services Commission and Collin County Community Supervision and Corrections Department) and Minnesota multistate cooperative purchasing (MMCAP, administered by Minnesota Department of Administration). The Collin County RFP 2026-327, due July 23, 2026, procures offender specimen collection and drug testing services valued at $600,000 over two years with renewal options, requiring immunoassay screening and LC/MS/MS or GC/MS confirmation across two collection sites. The Minnesota MMCAP RFP S1070000015802, due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals evaluated primarily on price competitiveness (75 percent) and compliance with cGMP and DSCSA standards. The Texas HHS Commission RFI HHS0017013, posted April 3, 2026, gathers market intelligence on direct-to-manufacturer prescription programs rather than committing to specific procurement volumes or budgets. The code does not reflect current demand for the specific pharmaceutical compound it nominally describes and warrants reclassification or detailed review of posting practices before pursuit.